Global Vaccines seeks partners to the technologies listed below and seeks new technologies.  Learn more here...

This technology is a new type of biological adjuvant designed to greatly enhance both systemic and mucosal immunity when used in combination with inexpensive killed virus and subunit vaccines.  The adjuvant technology has the capability of decreasing cost by a factor of ten or greater, increasing the effectiveness of some existing vaccines, and making other vaccines possible.  GVI has been awarded a National Institutes of Health research grant (funded through 2010) of $5.3 million to study the adjuvant effect and to determine its utility in nonhuman primates.  One of the grant reviewers stated that the technology, “represents a significant advance in the field of vaccination.”  A manuscript describing the technology has been published in the Proceedings of the National Academy of Sciences (volume 103, pp 3722-3727, 2006). 

This technology describes creating new live attenuated vaccines from scratch by combining different pieces of vaccine viruses and disease causing viruses together into a new vaccines strain.  GVI is applying this to the creation of a new type of vaccine for HIV, specifically for the strain of the virus circulating in sub-Saharan Africa.  This work is being funded by the International AIDS Vaccine Initiative (IAVI).  This milestone driven grant extends through 2012 with a budget of $1.2 million for the first two years.  Through a recent grant to IAVI awarded by the Bill and Melinda Gates Foundation, GVI has secured additional funding for this project ($1.7 million for 5 years through 2011).

Counterfeit, gray market, and illegally reimported products contribute to the problem of vaccine access for poor countries.  Global Vaccines has a sublicense to novel product authentication technology so that it may integrate anticounterfeiting measures into vaccine product design as means for making vaccines more accessible.  Read more about this sublicense here.